Monomethyl Fumarate
Isolated Plasmacytoma of Bone
Fred Hutchinson Cancer CenterSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Isolated Plasmacytoma of Bone cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Margarida Magalhaes-Silverman | Phase 2 | B |
METHOTREXATE Fred Hutchinson Cancer Center | Phase 2 | B |
Thalidomide Margarida Magalhaes-Silverman | Phase 2 | B |
Bortezomib Margarida Magalhaes-Silverman | Phase 2 | B |
FILGRASTIM Margarida Magalhaes-Silverman | Phase 2 | B |
View all 23 →
Same molecule, other indications
Monomethyl Fumarate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →